Precigen, Inc. Common Stock
PGENPrecigen, Inc. is a biotechnology company focused on the development of gene and cell therapies, immunotherapies, and advanced genetic medicines. It aims to address unmet medical needs across various indications, including cancer, infectious diseases, and autoimmune disorders, through innovative platform technologies and proprietary scientific approaches.
Company News
Precigen CFO Harry Thomasian Jr. sold 200,000 shares worth $1.1 million in early July 2026, reducing his direct holdings by 36%. However, the sale was part of a pre-arranged Rule 10b5-1 trading plan and should not be viewed as a red flag. The biotech company has shown strong momentum with Q1 revenue of $23.3 million and FDA orphan drug status for...
Precigen (NASDAQ: PGEN) reported Q1 2026 results showing strong momentum for its FDA-approved product PAPZIMEOS, which generated $21.6 million in net product revenue in its first full quarter post-launch. The company achieved approximately 400 patient hub enrollments with 25% from community settings, secured broad payer coverage spanning over 90%...
Patient Capital Management increased its stake in Precigen by 10.2 million shares in Q3 2025, valuing the transaction at approximately $28.78 million. The investment represents 3.48% of the fund's assets under management, following Precigen's significant stock price surge after FDA approval of Papzimeos.
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Precigen has submitted a biologics license application to the FDA for PRGN-2012, a potential first treatment for recurrent respiratory papillomatosis. The submission is a significant step forward, as PRGN-2012 has received Breakthrough Therapy and Orphan Drug Designations from the FDA.
